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Background: There is little data on responses to combination antiretroviral therapy (cART) among HIV-infected
children in the West African region. We describe treatment outcomes among HIV-1 and HIV-2 infected children
initiating cART in a research clinic in The Gambia, West Africa.
Methods: All treatment naive HIV-infected children who initiated cART according to the WHO ART guidelines for
children between October 2004 and December 2009 were included in the analysis. Kaplan-Meir estimates and sign-
rank test were used to investigate the responses to treatment.
Results: 65 HIV-1 and five HIV-2 infected children aged< 15 years were initiated on cART over this time period. HIV-1
infected children were treated with a combination of Zidovudine or Stavudine + Lamivudine+Nevirapine or Efavirenz
while children with HIV-2 were treated with Zidovudine+ Lamivudine+ ritonavir-boosted Lopinavir. HIV-1 infected
children were followed-up for a median (IQR) duration of 20.1 months (6.9 – 34.3), with their median (IQR) age at
treatment initiation, CD4% and plasma viral load at baseline found to be 4.9 years (2.1 – 9.1), 13.0% (7.0 – 16.0) and 5.4
log10 copies/ml (4.4 – 6.0) respectively. The median age at treatment initiation of the five HIV-2 infected children was
12 years (range: 4.6 – 14.0) while their median baseline CD4+ T cell count and HIV-2 viral load were 140 cells/mm3
(Range: 40 – 570 cells/mm3) and 4.5 log10copies/mL (Range: 3.1 - 4.9 log10copies/mL) respectively.
Among HIV-1 infected children <5 years of age at ART initiation, the median (IQR) increases in CD4% from baseline to
12, 24 and 36 months were 14% (8 – 19; P= 0.0004), 21% (15 – 22; P= 0.005) and 15% (15 – 25; P= 0.0422) respectively,
while the median (IQR) increase in absolute CD4 T cell count from baseline to 12, 24 and 36 months for those ≥5 years
at ART initiation were 470 cells/mm3 (270 – 650; P = 0.0005), 230 cells/mm3 (30 – 610; P = 0.0196) and 615 cells/mm3
(250 – 1060; P = 0.0180) respectively. The proportions of children achieving undetectable HIV-1 viral load at 6-, 12-, 24-
and 36 months of treatment were 24/38 (63.2%), 20/36 (55.6%), 8/22 (36.4%) and 7/12 (58.3%) respectively. The
probability of survival among HIV-1 infected children after 12 months on ART was 89.9% (95% CI 78.8 – 95.3). CD4 T cell
recovery was sub-optimal in all the HIV-2 infected children and none achieved virologic suppression. Two of the HIV-2
infected children died within 6 months of starting treatment while the remaining three were lost to follow-up.
Conclusions: The beneficial effects of cART among HIV-1 infected children in our setting are sustained in the first
24 months of treatment with a significant improvement in survival experience up to 36 months; however the outcome
was poor in the few HIV-2 infected children initiated on cART.* Correspondence: uokomo@mrc.gm
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Initiatives to increase access to antiretroviral therapy
(ART) for paediatric populations in resource-limited set-
tings, particularly the integration of HIV treatment and
care for children into existing adult ART centres as well
as maternal newborn and child health services, have
resulted in a significant increase in the numbers of chil-
dren starting treatment over the last couple of years [1].
In Sub-Saharan Africa where the global paediatric HIV
burden is situated there are however wide sub-regional
differences in paediatric ART coverage with greater ac-
cess seen in high-prevalence countries in Eastern and
Southern Africa compared with Western and Central
Africa [1].
Gambia has a concentrated but low-level mixed epi-
demic with estimated prevalence of HIV-1 and HIV-2
infection of 1.6% and 0.4% respectively from the 2008
national sentinel surveillance data [1,2]. Confined mostly
to West Africa, HIV-2 is noted to be less pathogenic
than HIV-1 with prolonged asymptomatic phase [3,4]
however, disease progression to HIV-2 associated-AIDS
does occur and is indistinguishable from that of HIV-1
[5,6]. In the absence of preventive interventions, peri-
natal transmission rates of HIV-2 range from 0 – 4% [7-
10]. It is estimated that there are currently fewer than
1000 children under 15 years of age known to be living
with HIV in The Gambia of whom approximately one-
third are receiving life-saving ART [11]; however, sub-
optimal coverage of prevention of mother-to-child-trans-
mission (PMTCT) services nation-wide, poor follow-up
of HIV-exposed infants and children and the general
inability to perform diagnostic virologic tests on
infants< 18 months of age suggest that HIV-infected
children are underestimated.
Data on treatment outcomes from paediatric ART pro-
grammes in the West African sub-region is limited to
countries with a high burden of paediatric HIV, and
describe only HIV-1 infected children [12-15]. Very few
studies have described survival of ART-naïve HIV-2-
infected children [16,17], and in contrast to HIV-1, little
is known about the best approach to the clinical treat-
ment and care of children infected with HIV-2 using
antiretroviral drugs developed against HIV-1[18].
We report the experiences of ART-naïve HIV-1 and
HIV-2 infected Gambian children starting ART at a
major paediatric HIV referral clinic at the Medical
Research Council (MRC) Unit in Fajara, The Gambia –
West Africa.
Methods
Study setting and participants
The MRC Fajara HIV clinical cohort was established in
1986 with approval from the Joint Gambia Government/
MRC Ethics Committee and enrolment of children intothe cohort started in 1993, based on written informed
consent by the parent or legal guardian. The cohort ini-
tially consisted of children whose HIV-infected parents
were enrolled in a natural history cohort, and later chil-
dren identified as HIV-infected and clinically in need of
treatment referred from other health-care facilities. The
Fajara clinic has been the only centre in the country per-
forming virological tests for the diagnosis of HIV infec-
tion in children <18 months of age and became the
major paediatric HIV referral clinic in The Gambia.
Provision of ART in The Gambia began in October 2004
through the support of the Global Fund to fight AIDS,
Tuberculosis and Malaria. Recruitment of children into
the programme ended in January 2010 as part of the
transition process transfer patient care from the MRC to
the Gambian national health care system.
Between June 2004 (when sensitization of patients in
preparation for the introduction of ART commenced)
and December 2009, a total of 332 ART-naïve HIV-
infected children were enrolled in the paediatric cohort
of whom 316 (95.2%) were HIV-1 and 16 (4.8%) HIV-2
positive (Figure 1). At enrolment, data on socio-
demographic characteristics were collected and a base-
line assessment conducted to determine clinical stage
and screen for opportunistic/concomitant infections;
CD4 T-cell profile, complete blood count and serum
biochemical indices were also measured. All clinical ser-
vices and treatments (including ART) were provided free
of charge and the patients also received reimbursement
of their transport costs to and from the clinic at every
clinic/ counselling visit whether on ART or not. Under
the orphans and vulnerable children (OVC) programme,
nutritional support was provided, including infant milk
formula for children up to 18 months of age whose
mothers opted not to breast-feed, as well as energy-rich
complementary feeds. School fees were also paid for all
children enrolled in school up till the age of 18 years.
Study procedures
Eligibility for initiating ART was based on the standard
WHO guidelines that were in place at the time of enrol-
ment [19,20]. In addition, all children were required to
have at least one identifiable caregiver who would take
responsibility for the administration of the child’s medi-
cations. Caregivers underwent a minimum of four pre-
ART counselling sessions over a period of three to six
weeks. ART was initiated only after approval by a na-
tional ART eligibility committee which reviewed the
clinical and social data of all children whose caregivers
had completed the pre-treatment counselling. At initi-
ation of therapy, a baseline physical assessment was con-
ducted and a blood sample drawn for determination of
baseline CD4+ T cell profile, HIV RNA plasma viral load,
complete blood count and serum chemistry.


























Figure 1 Flowchart of ART-naïve HIV-infected children< 15 years of age enrolled in the MRC Fajara paediatric HIV programme from
June 2004 - September 2009.
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ART was initiated in accordance with The Gambian
Department of State for Health guidelines [21]. The
first-line regimen for HIV-1 infected children consisted
of zidovudine (AZT) and lamivudine (3TC) in combin-
ation with nevirapine (NVP). AZT was replaced by Sta-
vudine (d4T) for children with a haemoglobin< 8 g/dl
while NVP was replaced by Efavirenz (EFV) for children
over 3 years of age (or >10Kg) who were receiving con-
current treatment for tuberculosis. The first-line regi-
men for HIV-2 infected children consisted of a
combination of AZT, 3TC and ritonavir-boosted lopina-
vir (LPV/r). Drugs were administered as syrups, single-
drug formulations, alone or in combination with adult,
generic fixed-dose combination tablets cut in half or
quartered. All children received daily cotrimoxazole
prophylaxis in accordance with WHO guidelines [22,23].Follow-up
Following ART initiation children were followed up at
2 weeks, 4 weeks, and then at monthly intervals for the
first 3 months and quarterly thereafter. At each visit,
patients were seen by a physician. Haematologic tests
and biochemical tests for liver function were performed
at the week 4 and quarterly follow-up visits. CD4+ T cell
profile, HIV RNA plasma viral load were measured at 3-
and 6-months and thereafter every 6 months or as clin-
ically indicated. Data on drug dispensing was collected in
the pharmacy registry database. Adherence was assessed
at each visit by pill counts (for children receiving tablets)
and/or self report of the care-giver or child. Patients withobserved adherence problems were offered further coun-
selling. Immunologic and virologic responses to ART were
assessed by changes in the CD4+ T cell parameters and
plasma viral load levels respectively from the pre-therapy
levels. An undetectable viral load was defined as being
<100 copies/mL. Patients who did not come to the clinic
for at least 90 days beyond their last drug-refill visit were
considered lost to follow up and where prior consent
obtained, were visited at home by trained field workers to
ascertain survival status or change of address.
Laboratory methods
HIV diagnosis
Sequential assays were carried out for serological diagno-
sis of HIV in children ≥18 months of age. Murex HIV
antibody test (ELISA) were carried out first on all serum
samples; a positive sample was presumed to contain anti-
bodies to HIV 1 or HIV-2. This was followed by Hexagon
HIV test for qualitative detection of IgG, IgA and IgM
antibodies to HIV-1 and HIV-2, which differentiates be-
tween HIV-1 and HIV-2 seropositivity. A coloured band
at line 2 and a coloured band at the control line indicate
HIV-2 seropositivity. In children <18 months of age, HIV
infection was diagnosed by two polymerase chain reaction
(PCR) tests. The MRC Fajara HIV clinic is the only centre
in The Gambia performing virological tests for the diag-
nosis of HIV infection in children <18 months of age.
HIV RNA viral load
Viral load testing was done using a quantitative polymer-
ase chain reaction method with 100 – 1,000,000 copies/ml
as the limit of detection. This method of viral load
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boratories, The Gambia [24]. Genotypic resistance testing
was not available due to cost.CD4 count measurement
Percentages and absolute counts of CD4 T lymphocytes
were determined on a FACS Calibur (Becton Dickinson,
US) using BD MultiTest reagents and MultiSet software
(BD Immunocytometry Systems).Statistical analysis
All treatment-naive children who initiated ART at the
MRC HIV clinic between 1 October 2004 and 31 De-
cember 2009 were included in this analysis; children
transferred into the cohort having been on ART else-
where were excluded. For the purpose of this analysis,
children who initiated treatment before 2006 were retro-
spectively re-staged at the time of starting ART
according to the 4-stage WHO paediatric HIV clinical
classification. Observation time for each child started at
the date of commencement of ART and ended either on
the 31st of December 2009 or at the date of death or the
date the child was last known to be alive, whichever
came first.
The main outcomes for this study were changes in im-
munologic and virologic parameters measured after initi-
ating ART. Baseline parameters were taken as the
nearest measurement within 3 months prior to initiation
of ART; whereas the subsequent 6-monthly monitoring
tests parameters were the nearest measurement within
a ± 3-month window of the respective time point after
initiation of ART. Differences between baseline and each
6-monthly follow-up CD4 measurement were deter-
mined using the Wilcoxon signed test. Kaplan-Meier
estimates were used to determine the time to achieve-
ment of an immunological response to ART and prob-
ability of survival. The time to achieve an immunological
response was defined as the interval between the base-
line CD4% and an increase in the CD4% of 5-, 10-, and
15-percentage points. An undetectable viral load was
defined as a viral load of< 100 copies/ml. The propor-
tion of children achieving undetectable viral load after 3-
, 6-, 12-, 18-, 24-, 30- and 36 months of treatment re-
spectively was estimated for all children with available
measurements at each specified time-point. Virological
failure was defined as having HIV RNA viral load >5000
copies/mL after 24 weeks (6 months) of therapy. Differ-
ences in baseline viral load and CD4+ T cell profiles be-
tween children who died and those who survived were
assessed using Wilcoxon rank sum tests. All statistical
analyses were performed with STATA Version11 (Stata
Corp., College Station, TX, USA) and statistical signifi-
cance defined as p<0.05 (two-sided).Results
Between October 1, 2004 and December 31, 2009, 70
treatment-naïve HIV- infected children less than 15 years
of age were initiated on ART in the MRC paediatric HIV
cohort. Sixty-five (92.9%) children were HIV-1 infected
and 5 (7.1%) HIV-2 infected. The children were followed
up for a median duration of 18.2 months (IQR: 5.7 –
34.3 months) during which time a total of eight children
(11.4%) died and 12 (17.1%) were lost to follow-up.Baseline characteristics of HIV-infected children on ART
Characteristics of HIV-1-infected children
The 65 HIV-1 infected children had a median duration of
follow-up of 20.1 months (IQR: 6.9 – 34.3 months) with
50 (76.9%) of the children having at least 6 months follow-
up after the start of ART. Thirty-one children (47.7%)
were female. The median age at start of treatment was
4.9 years (IQR: 2.1 - 9.1 years); 15 children (23.1%) were
less than 2 years of age. Twenty-seven (41.5%) children
had advanced (stage 3) or severe (stage 4) clinical disease,
18 of whom were also severely immunosuppressed (base-
line CD4% <15%) and 9 of whom had pulmonary tuber-
culosis. Baseline characteristics of the HIV-1 infected
children are presented in Table 1.
Both parents of seven (10.8%) children were known to
be HIV-positive; 41 (63.1%) children had at least one
parent known to be HIV-positive; and the HIV status of
both parents were negative or unknown in 3 (4.6%) and
14 (21.5%) of the children respectively. Five (7.7%) chil-
dren had lost both parents, 34 (52.3%) had both parents
alive while 22 had lost at least one parent.
Fifty-four (83.1%) children were commenced on
AZT+ 3TC+NVP; six (9.2%) on AZT+ 3TC+EFV and
five (7.7%) on d4T+ 3TC+NVP. Twelve (18.5%) of the
children had a substitution of at least one antiretroviral
drug while 4 (6.2%) among the 12 subsequently had a
second drug substitution during follow-up. The main
reasons for drug substitution were severe anaemia and/
or treatment for tuberculosis.Characteristics of HIV-2-infected children
The median duration of follow-up among the HIV-2-
infected children was 3.8 months (Range: 1.8 –
37.5 months). Three of the children were male and 2 were
female. The baseline clinical and laboratory characteristics
of the five HIV-2 infected children are presented in
Table 2. Their median age at the start of treatment was
12 years (Range: 4.6 – 14.0 years); four (80%) of the chil-
dren had advanced or severe clinical HIV disease at the
start of treatment. The median baseline CD4+ T cell count
and baseline HIV-2 viral load were 140 cells/mm3 (Range:
40 – 570 cells/mm3) and 4.5 log10copies/mL (Range: 3.1 -
4.9 log10copies/mL) respectively.
Table 1 Baseline characteristics of HIV-1 infected children
starting ART in the MRC Paediatric HIV Cohort, The
Gambia
Characteristics HIV-1 (n = 65)
Male [No (%)] 34 (52.3%)
Female [No (%)] 31 (47.7%)
Age, years [median (IQR:)] 4.9 (2.2 – 9.1)
Age distribution [No. (%)]
< 2 years 15 (23.1%)
2 – 4 years 19 (29.2%)
≥ 5 years 31 (47.7%)
Parent status [No. (%)]
Both parents alive 34 (53.3%)
Only mother living 6 (9.2%)
Only father living 16 (24.6%)
Both parents dead 5 (7.7%)
Unknown 4 (6.2%)
WHO Paediatric Clinical stage [No. (%)]
Stage 1 26 (40.6%)
Stage 2 12 (18.5%)
Stage 3 19 (29.2%)
Stage 4 8 (12.3%)
Immunologic category (CD4+%) [No. (%)]
>25% 1 (1.6%)
15% – 25% 25 (39.7%)
<15% 37 (58.7%)
Baseline CD4+% [median (IQR); n = 63 a] 13 (7 – 16)
< 2 years (n = 14) 13 (6 – 16)
2 – 4 years (n = 18) 14.5 (11 – 18)
≥ 5 years (n = 31) 10 (7 – 15)
Baseline CD4+ count [median (IQR); n = 62 b] 390 (210 – 730)
< 2 years (n = 13) 510 (300 – 1100)
2 – 4 years (n = 18) 615 (280 – 1020)
≥ 5 years (n = 31) 285 (100 – 520)
Baseline Viral load, log10copies/mL
[median (IQR); n = 55c]
5.4 (4.5 – 6.0)
a2 missing values; b3 missing values; c10 missing values.
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Immunologic response to treatment
Overall, the median (IQR) CD4% increased significantly
from 13% (7 – 16) at baseline to 23.3% (18.0 – 28.5;
p< 0.001), 27% (20 – 34; p< 0.001), and 27.5% (16 – 36;
p< 0.001) at 6-, 12- and 18 months respectively (Table 3).
Among those aged less than 5 years at initiation of
ART, the median (IQR) CD4% increase from baseline to
6-, 12 and 18 months of therapy was 12.3% (8 – 14; P
< 0.001), 14% (8 – 19; P = 0.0004) and 18% (13 – 22;
p = 0.0048) respectively. (Figure 2)CD4+ T cell count were used to assess rate of im-
munological recovery in children ≥ 5 years of age at the
start of ART. The median (IQR) increase in absolute
CD4+ T cell count from baseline to 6-, 12- and
18 months of therapy was 210 cells/mm3 (67.5 – 380;
P = 0.0009), 470 cells/mm3 (270 – 650; p = 0.0005) and
375 cells/mm3 (−62.5 – 835; p = 0.0085). (Figure 3)
The Kaplan-Meir curves in figures 4A – C show the
evolution of the CD4% of the all HIV-1-infected children
on ART during the follow-up period. The median times
to achieve 5%, 10% and 15% increases in the CD4% were
2.9 months (IQR: 2.8 – 5.8); 5.6 months (IQR: 2.9 –
11.1) and 10.3 months (5.5 – 17.1) respectively.Virologic response to treatment
At Six months of treatment, 24 (63.6%) of the 38 chil-
dren with available viral load measurements had
achieved complete virologic suppression (i.e. a viral load
<100 copies/mL); 7 (18.4%) children had virologic fail-
ure (i.e. a viral load> 5000 copies/mL), while 7 (18.4%)
children had incomplete virologic suppression (i.e.
5000> viral load >100 copies/mL). The suppression of
detectable viral load was achieved in 55.6%, 36.4% and
58.3% of children at 12, 24 and 36 months of follow-up
respectively (Table 4).
During the period of follow-up, only eight children
were switched to second-line therapy as a result of treat-
ment (virologic) failure); four (50%) of these children
were less than 5 years of age when they started first-line
therapy. The median time to initiation of second-line
therapy was 23.5 months (IQR: 15.8 – 30.7). Six of these
children eventually achieved complete virologic suppres-
sion whilst the remaining two achieved viral loads
<5000 copies/mL.Clinical outcomes
One child was transferred to another ART centre for
continued care and 8 (12.3%) were lost to follow-up of
whom one was withdrawn from the programme to seek
alternative (herbal) treatment. Six (9.2%) HIV-1-infected
children died after initiating ART; the median time to
death was 31.5 days (range: 6 – 231 days). Five (83.3%)
of the deaths occurred within 6 months of starting treat-
ment; four of which took place in within the first 90 days.
All the children but one were< 2 years of age at the
time of death however, all had WHO clinical stage 3 or
4 disease. Children who died had significantly lower
CD4% at baseline than those who survived (3.5% vs. 13%
respectively; P = 0.004), while baseline viral loads did not
differ (5.7 vs. 5.3 log10copies/mL respectively; P = 0.647).
The probability of survival on ART among the HIV-1-
infected children after 12 months was 89.9% (95% CI
78.8 – 95.3%) (Figure 5).
Table 2 Demographic, laboratory and clinical summary of HIV-2 infected children on antiretroviral therapy
Patient Sex Age at
diagnosis (years)







1 F 11 Both parents alive;
HIV status unknown
12 40 (1%) Nil WHO stage 4 at start of ART Clinical
follow-up for 2 months No follow-up
laboratory data; Died




14 280 (27%) 4.5 WHO stage 4 at start of ART Clinical
follow-up for 38 months Sub-optimal
CD4 recovery; >0.5 log10 increase in
viral load at 12 weeks; did not achieve
virologic suppression throughout
follow-up; LTFU
4 F 2 Both parents HIV-2
positive and alive
(both on ART)
4 570 (13%) 4.6 WHO stage 3 at start of ART Clinical
follow-up for 10 months No CD4 cell
gain; ART discontinued at 29 weeks
due to poor adherence; No follow-up
viral load data; LTFU




6 140 (4%) 3.1 WHO stage 3 at start of ART Clinical
follow-up for 4 months No follow-up
laboratory data; Died




12 110 (8%) 4.9 WHO stage 2 at start of ART Clinical
follow-up for 3 months Achieved an
increase in CD4 count of 50 cells/mm3
but a 1.0 log10 increase in viral load
at 12 weeks; LTFU
NOTE. LTFU= Lost to follow-up; EPTB = Extra pulmonary tuberculosis; PTB = Pulmonary tuberculosis.
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Two of the five HIV-2-infected children initiated on
ART died and the remainder were lost to follow-up.
One of the deaths occurred in a 12-year girl who started
ART five months after diagnosis. She had difficulty toler-
ating the ART with persistent nausea, vomiting and diar-
rhoea which did not respond to therapy. Her weight
dropped to 11.5 kg at 7th week of treatment and she
developed sepsis with anaemia and thrombocytopaenia.
She died after 2 months on ART. The second death oc-
curred in a 6-year-old boy with unexplained severe an-
aemia which was refractory to treatment; he died of
anaemic heart failure after 4 months on ART.
Among those lost to follow-up, CD4 T-cell recovery was
sub-optimal and none achieved virologic suppression.
Their clinic visitation was characterised by irregularTable 3 Immunologic response to antiretroviral therapy amon
Increase in CD4% from baseline following initiation of ART in all childre
Duration of follow-up (months) Number of children a Median CD
6 42 23.3% (18
12 37 27% (20
18 30 27.5% (1
24 25 29% (21
30 19 32% (19
36 12 30.3% (22
a Number of children tested at corresponding length of follow-up. Attrition in numb
b Wilcoxon signed ranks test.attendance associated with poor social and treatment sup-
port resulting in sub-optimal adherence to therapy. Fur-
ther details including socio-demographic characteristics of
the five HIV-2-infected children are shown in Table 2.
Discussion
The objective of ART in the treatment of HIV disease is
to inhibit viral replication and achieve and sustain viral
suppression while promoting immune reconstitution
and clinical improvement. There is increasing evidence
from sub-Saharan Africa that under routine program
conditions, HIV-infected children receiving ART can
achieve improved immune function, sustained virological
suppression and good clinical outcomes [25]. Ours is the
first study to report the early and medium-term immuno-
virological outcomes of ART-naïve HIV-1 and HIV-2g HIV-1-infected children
n (n = 65)
4% (IQR) Median CD4% increase from baseline (IQR) Pb
.0 – 28.5) 11% (4 – 15) < 0.001
– 34) 15% (7 – 20) < 0.001
6 – 36) 17% (6 – 22) < 0.001
– 38) 18.5% (5 – 22) 0.0001
– 38) 15% (9 – 24) 0.0001
.5 – 39.5) 18.5% (10.8 – 24.5) 0.002
ers is attributable to lack of data, loss to follow-up or death.
Figure 2 CD4% changes of HIV-1 infected children in the MRC Fajara cohort in response to ART. Median CD4% and median increase in
CD4% from baseline among HIV-1 infected children <5 years of age at ART start.
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prevalence setting of The Gambia – West Africa.
Despite a median baseline CD4 T cell percent of 13%,
which indicates that the HIV-1 infected children in this
cohort were at an advanced stage of immunosuppression
at entry, the overall median CD4 T cell percent
increased to 23.3% and 27% at six and 12 months re-
spectively, with a ‘plateau’ at 18 and 24 months. By this
measure, the MRC paediatric cohort demonstrated an
immediate and significant response to therapy. These
observed early- and medium-term responses are com-
parable to reports from a review of 28 paediatric cohortsFigure 3 Absolute CD4 T-cell count changes of HIV-1 infected childre
CD4 T-cell count and median changes in CD4 T-cell from baseline amongin Sub-Saharan Africa which showed that CD4%
increased within the first year of treatment with a plat-
eau after 12 to 18 months of treatment [25]. When
stratified by age however, children< 5 years of age at the
start of ART in our cohort achieved a sustained increase
in CD4% until 30 months of treatment, after which a de-
cline in the median change was observed. This could be
explained partially by the anticipated decrease in CD4%
with age during the first 5 years of life [26]. Likewise,
children≥ 5 years at start of ART had an initial increase
in absolute CD4 count up to 12 months followed by a
more blunted CD4 T cell recovery subsequently. Thesen in the MRC Fajara cohort in response to ART. Median absolute
HIV-1 infected children ≥5 years of age at ART start.
Figure 4 Kaplan Meier plots for increase in CD4% from baseline among HIV-1 infected children. Kaplan Meier survival curves of increase
in CD4% from baseline with time with plots A, B and C showing time to (A) 5%, (B) 10% and (C) 15% increase in CD4% from baseline.
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apparent mid-term ‘plateau’ in CD4 T cell recovery
which we observed in our cohort is comparable to
reports in other settings [27,28].
The proportion of HIV-1-infected children who achieved
an undetectable viral load, defined as HIV RNA <100 cop-
ies/mL, was 63.2% at six months. By 12- and 24- months of
therapy, 55.6% and 36.4% of the children in the cohortTable 4 Virologic response to antiretroviral therapy among H








a Denominators represent the number of children with the corresponding length o
b Percentage of those with a viral load measurement at each time point.respectively had undetectable viral loads. However, the pro-
portion increased to 58% at 36 months. Possible explana-
tions for this include the fact that some children who failed
therapy were switched on to second-line regimens as stated
in the results section, as well as the effect of reinforced ad-
herence counselling. Second-line therapy was however fre-
quently delayed as a result of shortages of appropriate
medicines and formulations.IV-1-infected children









Number at risk 65 50 38 34 28 21 16 9 5
Figure 5 Kaplan Meier plot showing survival probability among HIV-1 infected children on ART in the MRC Fajara Paediatric cohort,
The Gambia.
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within the first 90 days, with these early mortality pre-
dominantly among those with HIV-1 infection and aged
<2 years. This is similar to reports elsewhere in the sub-
region where early mortality (i.e. in the first 90 days of
ART) is substantially higher compared to later months
[29-32]. The estimated 12 months survival probability
on ART among the HIV-1-infected children of 89.9%
falls within range of 12 month survival probability
reported from the review of paediatric cohorts in sub-
Sahara Africa mentioned earlier [25]. Our findings show
sustained improvement in survival experiences which is
independent of the baseline CD4+ T cell percentage,
therefore reinforcing the obvious benefit of ART in a
routine program setting in a resource-limited setting
and the need to further scale-up access to ART in
children.
We found a very poor outcome among the six HIV-2
infected children after a median of 23 weeks on combin-
ation antiretroviral therapy, with three out of six being lost
to follow-up and two dying. A review of the available la-
boratory parameters for treatment monitoring similarly
showed poor immunologic and virologic responses in al-
most all of those children. A couple of factors could have
contributed to the poor clinical and immuno-virologic
outcomes we observed among the HIV-2 infected children
in this report. First, all the children were at an advanced
disease stage at diagnosis of their HIV-2 infection, and
initiated antiretroviral therapy at a point when they were
severely immunocompromised. Given the chronicity of
HIV-2 infection, the long duration of infection before
these children became eligible for ART at the same CD4
count threshold as HIV-1 infected children might havecontributed to the poor immunological recovery. Sec-
ondly, despite the progress made in scaling-up ART in
West Africa, treatment of HIV-2 infection still remains a
challenge and the optimal treatment option for HIV-2 in-
fection is still a subject of several ongoing research studies
focussing only on adults. While available data from adult
HIV-2 cohorts suggests a sub-optimal response to some
of the protease inhibitors (PIs) commonly used in the
West African sub-region [33,34], very little is known about
HIV-2 therapeutic approach in children. However, from
our report, it is difficult to conclude that a sub-optimal re-
sponse to LPV/r-based regimen that we use might have
contributed to the observed poor outcome in view of the
small number of cases.
Baseline co-morbidities such as tuberculosis, malnutri-
tion, helminthiasis, anaemia as well as ART toxicity or
immune reconstitution inflammatory syndrome (IRIS)
particularly in those with advanced immunosuppression
at ART initiation are well recognized risk factors for
poor outcomes on antiretroviral therapy including early
mortality [31,35,36]. Most HIV-infected children in
resource-limited settings present at an advanced stage of
disease with marked immunosuppression mostly because
of widespread lack of laboratory capacity for diagnosis of
HIV-infection in children less than 18 months of age,
who still harbour maternal HIV-antibodies. Although
many of the children in our cohort were children of
HIV-infected adults enrolled in a natural history cohort
who would have benefitted from early diagnosis, a good
number however, were referred from the MRC outpati-
ents’ clinic and hospital ward as well as other health-
care facilities due to chronic ill health and at an advanced
HIV disease clinic stage.
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viral suppression and treatment outcome [37], and in chil-
dren is strongly linked to the availability of treatment sup-
port. Although a limitation of this study is that adherence
as measured by pill counting and care-giver/self report
was not specifically analysed as a variable, the observed
immuno-virological responses were objective evidence of
the levels of adherence to medications within the cohort.
Reddi et al. [31] reported that having at least one HIV-
positive caregiver provides a protective effect against mor-
tality when compared with care-givers who were untested
or HIV-negative especially where this care-giver receives
treatment at the same site as such a care-giver. They
hypothesize that such a care-giver may be more
knowledgeable about symptom management and disease
progression and therefore able to provide more informed
treatment support. The majority of the children on ART
in our cohort had both parents alive and at least one HIV-
positive parent; we however did not analyze the effect of
care-giver HIV-status on treatment outcomes.
As with most other paediatric HIV treatment pro-
grammes in resource-limited settings [38,39], we resorted
to using adult, generic fixed-dose combination tablets cut
in half or quartered. In the absence of pill-cutters this usu-
ally resulted in unequal-sized fractions and could have in-
advertently contributed to inappropriate, particularly sub-
therapeutic, drug doses particularly with the LPV/r gel
capsules [40].
As more countries in the sub-region scale-up access to
ART for HIV-infected children, paediatric treatment out-
comes data can help guide programme implementation.
The level of care provided at our HIV clinic is however
not representative of paediatric HIV care in West Africa
as patients had the advantage of frequent and regular care
provided by highly qualified physicians and counsellors at
essentially no cost to the patients, with routine viral load
and CD4 cell counts and -percent monitoring. This,
coupled with the small size of our paediatric cohort makes
it difficult to generalize our findings to other settings in
the sub-region. We however experienced similar program-
matic challenges such as lack of appropriate paediatric for-
mulations of almost all the antiretroviral drugs especially
second-line drugs, and stock-out of at least one drug an-
nually. Over 60% of the children on our cohort were se-
verely immunocompromised at treatment initiation, and
the need for multiple pre-ART counselling sessions and
prior approval by the national Eligibility committee fur-
ther contributed to delays in starting treatment which
may have put these patients at increased risk of poor im-
munological recovery, treatment failure and mortality.
Conclusions
We have observed that the beneficial effects of antiretro-
viral therapy among Gambian children are sustained inthe first 24 months of treatment with a significant im-
provement in survival experience of up to 36 months.
Implementation of diagnostic PCR or an equivalent
technology for earlier HIV diagnosis, especially at mater-
nal and child-health clinics, and improved access to
paediatric fixed dose formulations to facilitate adherence
and appropriate dosing, are key to scaling up access to
life-saving ART for HIV-infected children.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We thank the field workers and nurses of the MRC HIV Clinic, particularly Mr.
Saydiba Tamba. We acknowledge and appreciate the efforts of Gilleh
Thomas and Mehedi Shams-Rony in acquisition of the data; Ramu Sarge-Njie,
Samuel Nyamweya, Sheikh Jarju, Clayton Onyango and Mathew Cotten for
their assistance with HIV diagnostics, CD4 and viral load measurements.
This work was supported by the Elizabeth Glaser Pediatric AIDS Foundation
[grant number: ILA # 01–15 to A.J]. Support for antiretroviral drugs and MRC
HIV Clinic Staff was provided by the Global Fund for AIDS, TB and Malaria
(GFATM)
Author details
1Medical Research Council (UK) Laboratories, Atlantic Road, Fajara273, Banjul,
The Gambia. 2Institute of Tropical Medicine, Nationalestraat 155, Antwerp
2000, Belgium. 3International Center for AIDS Care and Treatment Program
(ICAP)-Swaziland, Mailman School of Public Health Columbia University, New
York, USA. 4WAPHIR Network, Universite Cheikh Anta Diop Laboratoire de
Bacteriologie Virologie, Hopital A le Dantec, 30 Avenue Pasteur, Dakar,
Senegal.
Authors' contributions
UO coordinated the pediatric HIV clinical activities, performed the statistical
analysis and drafted the manuscript. TT contributed to the study design,
participated in the statistical analysis and helped to draft the manuscript. JT
participated in the statistical analysis. IP contributed to the design of the
study. TT, FO and KP participated in the clinical care of the patients. AJ
conceived the idea and gave overall support. All authors read and approved
the final manuscript.
Received: 20 July 2011 Accepted: 8 July 2012
Published: 8 July 2012
References
1. WHO, UNAIDS, UNICEF: Towards Universal Access: Scaling up priority HIV/
AIDS interventions in the health sector. In Progress Report 2010. Geneva:
World Health Organization; 2010.
2. National Sentinel Surveillance Working Group: National Sentinel Surveillance
Bulletin 2008. Banjul, The Gambia: Department of State for Health (DoSH);
2008.
3. Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-
Ferreira MO, Champalimaud JL, Montagnier L: Human immunodeficiency
virus type 2 infection associated with AIDS in West Africa. N Engl J Med
1987, 316:1180–1185.
4. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia
MC, Gueye EH, et al: Reduced rate of disease development after HIV-2
infection as compared to HIV-1. Science 1994, 265:1587–1590.
5. Morgan G, Wilkins HA, Pepin J, Jobe O, Brewster D, Whittle H: AIDS
following mother-to-child transmission of HIV-2. AIDS 1990, 4:879–882.
6. van der Loeff MF Schim, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E,
Alabi A, Bayang A, Ariyoshi K, Whittle HC: Mortality of HIV-1, HIV-2 and
HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The
Gambia. AIDS 2002, 16:1775–1783.
7. O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R, Whittle H:
Maternal plasma viral RNA levels determine marked differences in mother-
to-child transmission rates of HIV-1 and HIV-2 in The Gambia MRC/Gambia
Government/University College London Medical School working group on
mother-child transmission of HIV. AIDS 2000, 14:441–448.
Okomo et al. BMC Pediatrics 2012, 12:95 Page 11 of 11
http://www.biomedcentral.com/1471-2431/12/958. Adjorlolo-Johnson G, DeCock K, Ehounou E, et al: Prospective comparison
of mother-to-child transmision of HIV-1 and HIV-2 in Abidjan, Ivory
Coast. JAMA 1994, 272:462–466.
9. Andreasson PA, Dias F, Naucler A, Andersson S, Biberfeld G: A prospective
study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS
1993, 7:989–993.
10. Burgard M, Jasseron C, Matheron S, Damond F, Hamrene K, Blanche S, Faye
A, Rouzioux C, Warszawski J, Mandelbro L: Mother-to-child transmission of
HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort
EPF-CO1. Clin Infect Dis 2010, 51:833–843.
11. UNICEF: Unite for Children, Unite Against AIDS. Children and AIDS: The Fourth
Stocktaking Report. Geneva: UNICEF; 2009.
12. Adje-Toure C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou
O, Fassinou P, Bissagnene E, Kadio A, Nolan ML, Nkengasong JN: Virologic
and immunologic response to antiretroviral therapy and predictors of
HIV type 1 drug resistance in children receiving treatment in Abidjan,
Cote d'Ivoire. AIDS Res Hum Retroviruses 2008, 24:911–917.
13. Diack MA, Signate Sy H, Diagne Gueye NR, Ba A, Sylla A, Diouf S, Diagne I,
Sarr M, Sow HD: Epidemiological and clinical aspects of paediatric HIV
infections in Albert-Royer Paediatric Hospital Dakar, Senegal. Archives of
Pediatrics 2005, 12:404–409.
14. Elise A, France AM, Louise WM, Bata D, François R, Roger S, Philippe M:
Assessment of Adherence to Highly Active Antiretroviral Therapy in a
Cohort of African HIV-Infected Children in Abidjan, Cote d'Ivoire. Journal
of Acquired Immune Deficiency Syndromes 2005, 40:498–500.
15. Fassinou P, Elenga N, Rouet Fo, Laguide R, Kouakoussui KA, Timite M,
Blanche S, Msellati P: Highly active antiretroviral therapies among HIV-1-
infected children in Abidjan, Cote d'Ivoire. AIDS 2004, 18:1905–1913.
16. Ota MO, O'Donovan D, Alabi AS, Milligan P, Yamuah LK, N'Gom PT, Harding
E, Ariyoshi K, Wilkins A, Whittle HC: Maternal HIV-1 and HIV-2 infection
and child survival in The Gambia. AIDS 2000, 14:435–439.
17. van der Loeff MF Schim, Hansmann A, Awasana AA, Ota MO, O'Donovan D,
Sarge-Njie R, Ariyoshi K, Milligan P, Whittle H: Survival of HIV-1 and HIV-2
perinatally infected children in The Gambia. AIDS 2003, 17:2389–2394.
18. Gottlieb GS, Eholié S-P, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle
HC, Sow PS: A call for randomized controlled trials of antiretroviral
therapy for HIV-2 infection in West Africa. AIDS 2008, 22:2069–2072.
19. WHO: Scaling up antitertiviral therapy in resource limited settings: Treatment
guidelines for a public health approach (2003 Revision). Geneva: World Health
Organization; 2004.
20. WHO: Antiretroviral therapy for HIV infection in infants and children: towards
universal access recommendations for a public health approach. Geneva:
World Health Organization; 2006.
21. Department of State for Health: The Gambia: Antiretroviral Therapy: A manual
for health service providers. Banjul: New Type Press; 2004.
22. UNAIDS, WHO: Provisional WHO/UNAIDS Secretariat recommendations on the
use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in
Africa. Geneva: Joint United Nations Program on HIV/AIDS and World Health
Organization; 2000.
23. WHO: Guidelines on co-trimoxazole prophylaxis for HIV-related infections
among children, adolescents and adults: Recommendations for a public health
approach. Geneva: World Health Organization; 2006.
24. Damond F, Benard A, Ruelle J, Alabi A, Kupfer B, Gomes P, Rodes B, Albert J,
Boni J, Garson J, et al: Quality control assessment of human
immunodeficiency virus type 2 (HIV-2) viral load quantification assays:
results from an international collaboration on HIV-2 infection in 2006.
J Clin Microbiol 2008, 46:2088–2091.
25. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ: Effectiveness of
antiretroviral therapy among HIV-infected children in sub-Saharan Africa.
Lancet Infect Dis 2008, 8:477–489.
26. Denny T, Yogev R, Gelman R, et al: Lymphocyte subsets in healthy
children during the first 5 years of life. JAMA 1992, 267:1484–1488.
27. Resino S, Resino R, Leon JA, Bellon JM, Martin-Fontelos P, Ramos JT,
Gurbindo-Gutierrez D, de Jose MI, Ciria L, Munoz-Fernandez MA: Impact of
long-term viral suppression in CD4+ recovery of HIV-children on Highly
Active Antiretroviral Therapy. BMC Infect Dis 2006, 6:10.
28. Tarwater PM, Margolick JB, Jin J, Phair JP, Detels R, Rinaldo C, Giorgi J,
Munoz A: Increase and plateau of CD4 T-cell counts in the 3(1/2) years
after initiation of potent antiretroviral therapy. J Acquir Immune Defic
Syndr 2001, 27:168–175.29. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi
BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, et al: Clinical outcomes
and CD4 cell response in children receiving antiretroviral therapy at
primary health care facilities in Zambia. JAMA 2007, 298:1888–1899.
30. Wamalwa DC, Farquhar C, Obimbo EM, Selig S, Mbori-Ngacha DA,
Richardson BA, Overbaugh J, Emery S, Wariua G, Gichuhi C, et al: Early
Response to Highly Active Antiretroviral Therapy in HIV-1-Infected
Kenyan Children. J Acquir Immune Defic Syndr 2007, 45:311–317.
31. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ,
Mntambo M, Thomas M, Nixon K, et al: Preliminary outcomes of a
paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal
. South Africa. BMC Pediatr 2007, 7:13.
32. Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, Moultrie H, Prozesky
H, Technau K, Eley B, Vaz P, et al: Early mortality and loss to follow-up in
HIV-infected children starting antiretroviral therapy in Southern Africa.
J Acquir Immune Defic Syndr 2010, 54:524–532.
33. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine
W: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds:
implications for treatment and postexposure prophylaxis. Antivir Ther
2004, 9:57–65.
34. Adje-Toure CA, Cheingsong R, Garcia-Lerma JG, Eholie S, Borget MY,
Bouchez JM, Otten RA, Maurice C, Sassan-Morokro M, Ekpini RE, et al:
Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral
load, CD4+ cell counts, and drug resistance profiles of patients treated
in Abidjan, Cote d'Ivoire. AIDS 2003, 17(Suppl 3):S49–54.
35. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J,
Palumbo P, Koenig LJ, Bulterys M: Trends in opportunistic infections in the
pre- and post-highly active antiretroviral therapy eras among HIV-
infected children in the Perinatal AIDS Collaborative Transmission Study,
1986–2004. Pediatrics 2007, 120:100–109.
36. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier
C, dArminio Monforte A, Ledergerber B, Lundgren JD: Anaemia is an
independent predictive marker for clinical prognosis in HIV-infected
patients from across Europe. EuroSIDA study group. AIDS 1999, 13:943–950.
37. Mannheimer S, Friedland G, Matts J, Child C, Chesney M: The consistency
of adherence to antiretroviral therapy predicts biologic outcomes for
human immunodeficiency virus-infected persons in clinical trials. Clin
Infect Dis 2002, 34:1115–1121.
38. O'Brien DP, Sauvageot D, Zachariah R, Humblet P: In resource-limited
settings good early outcomes can be achieved in children using adult
fixed-dose combination antiretroviral therapy. AIDS 2006, 20:1955–1960.
39. Chokephaibulkit K, Plipat N, Cressey T, Frederix K, Phongsamart W,
Capparelli E, et al: Pharmacokinetics of nevirapine in HIV-infected children
receiving an adult fixed-dose combination of stavudine, lamivudine and
nevirapine. AIDS 2005, 19:1495–1499.
40. Ellis J, L'Homme R, Ewings F, et al: Nevirapine concentrations in HIV-
infected children treated with divided fixed-dose combination
antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007, 12:253–260.
doi:10.1186/1471-2431-12-95
Cite this article as: Okomo et al.: Treatment outcomes among HIV-1 and
HIV-2 infected children initiating antiretroviral therapy in a
concentrated low prevalence setting in West Africa. BMC Pediatrics 2012
12:95.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
